Last reviewed · How we verify
NCT04188951
HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer
EARLY_PHASE1 trial testing Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] in Head and Neck Neoplasms in 10 participants. Completed in 8 May 2024.
15 June 2023
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 4 October 2019 |
| Primary completion | 15 June 2023 |
| Estimated completion | 8 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] — full drug profile →
Conditions studied
- Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
Sponsor
Henry Ford Health System — full company profile →
Who can join
Adults 18 to 85, any sex, with Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a pilot study to explore the feasibility and efficacy of immunotherapy following salvage surgery for recurrent head and neck cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Salvage Surgery in Recurrent Oral Squamous Cell Carcinoma.
Shetty KSR, Kurle V, Greeshma P, Ganga VB, et al · · 2021 · cited 32× · PMID 35156084 · DOI 10.3389/froh.2021.815606
Verify or expand the search:
- PubMed search for NCT04188951
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Trials testing the same drug.
- NCT03637803 — Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors · Phase 1, PHASE2 · terminated
- NCT03480672 — Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamou · Phase 2 · completed
Other recruiting trials for Head and Neck Neoplasms
Currently open trials in the same condition.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
- NCT06998069 — Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · recruiting
- NCT07158164 — DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment · Phase 4 · recruiting
- NCT06303180 — NIDCD Otolaryngology Clinical Protocol Biospecimen Bank · recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04188951 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04188951.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing